查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014459

數位治療設備市場：2026-2032年全球市場預測（按治療領域、給藥方法、分銷管道和最終用戶分類）

Digital Therapeutic Devices Market by Therapeutic Area, Delivery Mode, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，數位治療設備市場價值將達到 87.1 億美元，到 2026 年將成長至 102.4 億美元，到 2032 年將達到 296.2 億美元，複合年成長率為 19.10%。

主要市場統計數據
基準年 2025 87.1億美元
預計年份：2026年 102.4億美元
預測年份 2032 296.2億美元
複合年成長率 (%) 19.10%

權威說明指出，臨床檢驗、監管演變和支付方合作正在重新定義數位治療設備，以實現永續的臨床整合。

在軟體開發、感測器技術和實證設計進步的推動下，數位治療設備已從實驗性介入措施發展成為經臨床檢驗的工具，成為傳統診療路徑的有力補充。近年來，法律規範日趨成熟，已將軟體視為醫療設備，支付方也開始認知到其在改善臨床療效和降低後續成本方面的提案。因此，產品開發的重點已轉向產生嚴謹的臨床證據、確保與電子醫療系統的互通性以及展現長期的病人參與。

人工智慧驅動的個人化、身臨其境型交付模式和基於價值的報銷如何融合，從而從根本上改變數位療法的採用、開發和臨床整合？

在技​​術突破和醫療保健系統變革的推動下，數位治療設備領域正經歷著一場變革。人工智慧 (AI) 和機器學習正在實現可隨時間推移而調整的個人化治療方案。同時，感測器精確度的提高和穿戴式裝置的進步使得持續生理監測成為可能，從而增強了患者的參與度和臨床相關性。諸如虛擬實境 (VR) 和擴增實境(AR) 等身臨其境型技術正在拓展治療方法，超越傳統的行動應用程式，為疼痛管理、認知訓練和暴露療法提供了新的治療機制。

評估 2025 年關稅調整對數位治療設備製造商的供應鏈韌性、籌資策略和定價方法的策略影響。

2025年新關稅措施的實施，為數位治療設備價值鏈上的相關人員帶來了新的營運和策略考量。對於依賴硬體的設備和從海外供應商採購的感測器組件而言，供應鏈成本趨勢尤其顯著。因此，各公司正在探索替代籌資策略，例如供應商多元化、協商成本分攤安排以及區域製造夥伴關係，以在不影響臨床規格的前提下維持獲利能力。

透過詳細的細分分析，闡明目標族群、劑型、最終用戶環境和分銷策略如何共同決定引入途徑和臨床影響。

細分市場層面的趨勢揭示了不同治療領域、劑型、終端用戶和分銷管道的不同發展機會。在治療領域方面，專注於心臟衰竭和高血壓的循環系統解決方案因其明確的臨床終點和與醫療團隊的頻繁互動而發展勢頭強勁；而針對1型和2型糖尿病的糖尿病管理解決方案則受益於與持續血糖監測和自動化胰島素輸注系統的緊密整合。針對焦慮、憂鬱症和壓力管理的心理健康產品需求旺盛，這主要得益於擴充性的遠距交付。同時，用於治療慢性疼痛和進行物理復健的肌肉骨骼介入措施正透過客觀的功能評估指標和遠端監測展現其價值。用於治療氣喘和慢性阻塞性肺病（COPD）的呼吸系統療法正利用與聯網吸入器和肺功能儀的整合來提高患者的用藥依從性並預防病情加重。

美洲、歐洲、中東和非洲以及亞太地區的區域戰略挑戰和實施模式，這些挑戰和模式會影響監管、商業和製造戰略。

區域趨勢差異顯著，影響開發商、支付方和醫療服務提供者的策略重點。在美洲，監管政策的明確化和基於價值的醫療試點計畫生態系統的不斷發展，促進了與支付方和醫療系統的合作，同時，支持將設備和軟體整合到慢性病管理中的商業性報銷途徑也日趨成熟。在歐洲、中東和非洲，各國法規結構和報銷政策的差異，使得制定區域性監管策略和有針對性的衛生經濟學證據成為必要，以確保成功部署；與大學附屬醫院的合作通常能夠提升試驗計畫的可信度和部署效率。在亞太地區，數位醫療的快速普及、行動網路的廣泛應用以及製造群帶來了規模經濟效益，但成功的商業化需要應對不同的管理體制，並實現語言和臨床路徑的本地化。

不斷發展的競爭策略、策略聯盟和基於證據的差異化正在重塑數位治療設備公司的產品定位和經營模式。

數位治療設備領域的競爭格局呈現出成熟醫療設備製造商、數位醫療Start-Ups以及來自消費科技​​公司的跨產業企業並存的局面。主要企業正努力透過提供臨床證據、建立可擴展的平台架構以及與製藥公司和醫療系統建立策略合作夥伴關係來脫穎而出，旨在將其產品整合到標準治療流程中。創業投資支援的創新者往往專注於快速迭代開發和特異性疾病的適應症，而成熟製造商則利用其監管方面的專業知識和供應鏈規模來加速軟硬體整合產品的市場推廣。

為高階主管提供可操作且優先考慮的建議，以協調臨床證據、互通性、供應鏈彈性和經營模式，以實現永續成長。

行業領導企業必須推動一系列綜合舉措，以確保臨床應用和商業性成功。首先，他們應優先創建符合支付方和醫療服務提供者決策標準的可靠臨床證據，利用可操作的試驗設計和真實世界數據來證明有意義的長期療效。其次，他們應設計可與電子健康記錄和臨床工作流程整合的互通性解決方案，以減輕臨床醫生的負擔並實現無縫資料交換。第三，他們應建構靈活的經營模式，包括基於療效的合約、與醫療系統試驗計畫以及反映部署環境的分級定價。

為了檢驗策略意義，我們採用了嚴格的混合方法研究，結合了專家訪談、臨床證據整合、監管分析和情境測試。

本分析所依據的研究採用了混合方法，結合了質性訪談、二手證據整合以及針對性的供應鏈和監管分析。訪談對象涵蓋了廣泛的相關人員，包括臨床醫生、保險公司、採購經理、醫療設備開發商和技術合作夥伴，旨在深入了解推廣應用的障礙和促進因素。二手分析則仔細審查了同行評審的臨床研究、監管指導文件、互通性技術標準以及公開的臨床試驗註冊信息，以整合有關療效、安全性和推廣應用考慮的證據。

一項綜合臨床、監管和營運重點的最終結論，將決定數位治療設備的領導地位和永續應用。

總之，數位治療設備領域正日趨成熟，成為一個以臨床為主導且具有商業性可行性的醫療保健服務分支，但成功需要證據、法規和商業策略的嚴格協調。那些投資於嚴謹的臨床檢驗、注重互通性設計以及與支付方合作的商業模式的開發商，將比競爭對手更具優勢。同時，供應鏈的韌性和本地化策略對於緩解貿易相關的成本壓力、確保生產和分銷的連續性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：數位治療設備市場：依治療領域分類

  • 循環系統
    • 心臟衰竭
    • 高血壓
  • 糖尿病管理
    • 1型糖尿病
    • 2型糖尿病
  • 心理健康
    • 焦慮
    • 憂鬱症
    • 壓力管理
  • 肌肉骨骼系統
    • 慢性疼痛
    • 物理復健
  • 呼吸系統
    • 氣喘
    • COPD

第9章：數位醫療器材市場：以交付方式分類

  • 移動的
  • 虛擬實境/擴增實境
  • 穿戴式裝置
  • Web

第10章：數位治療設備市場：依通路分類

  • 離線
  • 線上平台

第11章：數位治療設備市場：以最終用戶分類

  • 家庭環境
  • 醫院和診所
  • 研究機構

第12章：數位治療設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：數位治療設備市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 數位治療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國數位治療設備市場

第16章：中國數位醫療設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 2Morrow, Inc.
  • Akili Interactive Labs, Inc.
  • Big Health Ltd.
  • Biofourmis, Inc.
  • Canary Health, Inc.
  • Click Therapeutics, Inc.
  • CureApp, Inc.
  • DarioHealth Corp.
  • Kaia Health Software GmbH
  • MindMaze SA
  • Noom, Inc.
  • Omada Health, Inc.
  • Pear Therapeutics, Inc.
  • Propeller Health, Inc.
  • Teladoc Health, Inc.
  • Vida Health, Inc.
  • WellDoc, Inc.
Product Code: MRR-4348D129FA64

The Digital Therapeutic Devices Market was valued at USD 8.71 billion in 2025 and is projected to grow to USD 10.24 billion in 2026, with a CAGR of 19.10%, reaching USD 29.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.71 billion
Estimated Year [2026] USD 10.24 billion
Forecast Year [2032] USD 29.62 billion
CAGR (%) 19.10%

An authoritative introduction to how clinical validation, regulatory evolution, and payer alignment are redefining digital therapeutic devices for durable clinical integration

Digital therapeutic devices have evolved from experimental interventions to clinically validated tools that complement traditional care pathways, driven by advances in software development, sensor technology, and evidence-based design. In recent years, regulatory frameworks have matured to accommodate software as a medical device, and payer ecosystems have begun to recognize value propositions tied to improved clinical outcomes and reduced downstream costs. Consequently, product development priorities have shifted toward generating rigorous clinical evidence, ensuring interoperability with electronic health systems, and demonstrating long-term patient engagement.

As a result, commercialization strategies increasingly center on partnerships with health systems, payers, and pharmaceutical companies to embed therapeutics into standard care pathways. This trend has been reinforced by clinicians adopting digital therapeutics as adjunctive therapies to address chronic disease management challenges that are not fully resolved by pharmacological interventions alone. Looking ahead, developers who can align clinical validation, regulatory strategy, and reimbursement readiness will realize faster adoption curves and deeper integration into care delivery models. Transitional investments in privacy architecture, real-world evidence generation, and clinician-facing workflows are becoming non-negotiable to unlock durable commercial traction.

How AI personalization, immersive delivery modes, and value-based reimbursement are converging to fundamentally shift adoption, development, and clinical integration of digital therapeutics

The landscape for digital therapeutic devices is undergoing transformative shifts shaped by technological breakthroughs and systemic healthcare changes. Artificial intelligence and machine learning are enabling personalized therapeutic pathways that adapt over time, while advances in sensor fidelity and wearable form factors allow continuous physiological monitoring that enhances both engagement and clinical relevance. Immersive technologies such as virtual and augmented reality are expanding therapeutic modalities beyond traditional mobile applications, offering novel treatment mechanisms for pain modulation, cognitive retraining, and exposure-based therapies.

Concurrently, value-based care initiatives and outcome-driven reimbursement models are incentivizing stakeholders to adopt solutions that demonstrably improve care quality and reduce avoidable utilization. This alignment between clinical outcomes and commercial incentives is catalyzing strategic partnerships across the health ecosystem. Furthermore, growing patient expectations for convenient, home-based care are accelerating adoption of remote delivery modes, and interoperability standards are increasingly critical to ensure seamless integration with provider workflows. Taken together, these shifts are elevating clinical robustness, scalability, and the imperative for measurable real-world impact.

Assessing the strategic consequences of 2025 tariff adjustments on supply chain resilience, sourcing strategies, and pricing approaches across digital therapeutic device manufacturers

The imposition of new tariff measures in 2025 has introduced a fresh set of operational and strategic considerations for stakeholders in the digital therapeutic device value chain. Supply chain cost dynamics have become more prominent, particularly for hardware-dependent devices and sensor components sourced from overseas suppliers. Consequently, companies are evaluating alternative sourcing strategies, including supplier diversification, negotiated cost-sharing arrangements, and regional manufacturing partnerships to preserve margin structures without compromising clinical specifications.

In reaction to tariff-driven cost pressures, manufacturers are prioritizing design for manufacturability and component consolidation to reduce dependence on tariff-exposed inputs. In parallel, commercial teams are reassessing pricing approaches and contracting models to maintain payer and provider uptake while mitigating the risk of price-driven adoption slowdowns. Importantly, tariff impacts are not uniformly distributed; companies that can localize critical production steps or vertically integrate key components gain resilience and a competitive edge. Thus, strategic supply chain planning, contract flexibility, and early engagement with procurement and regulatory stakeholders are proving essential to navigate the evolving trade environment.

Deep segmentation insights revealing how therapeutic focus, delivery modality, end-user environment, and distribution strategy collectively determine adoption pathways and clinical impact

Segment-level dynamics reveal differentiated opportunity paths across therapeutic areas, delivery modes, end users, and distribution channels. Within therapeutic areas, cardiovascular solutions focused on heart failure and hypertension are gaining traction due to clear clinical endpoints and frequent touchpoints with care teams, whereas diabetes management solutions targeting type 1 and type 2 diabetes benefit from tight integration with continuous glucose monitoring and automated insulin delivery ecosystems. Mental health offerings addressing anxiety, depression, and stress management are experiencing strong demand driven by scalable remote delivery, while musculoskeletal interventions for chronic pain and physical rehabilitation demonstrate value through objective functional measures and remote monitoring. Respiratory therapies for asthma and COPD are leveraging connected inhaler and spirometry integrations to support adherence and exacerbation prevention.

Delivery mode is shaping user engagement and therapeutic mechanism: mobile-first applications provide ubiquitous access and broad reach, VR and AR solutions enable immersive therapeutic exposures and neurocognitive retraining, wearable devices support continuous physiologic measurement and closed-loop interventions, and web platforms offer clinician dashboarding and program management at scale. End-user environments influence design and deployment: solutions optimized for home settings prioritize ease of use, security, and asynchronous clinician interaction; hospital and clinic implementations demand integration with clinical workflows and rigorous validation; research institute deployments emphasize modular data export and protocol adherence. Distribution channels remain bifurcated between offline pathways, which rely on provider referral and institutional contracting, and online platforms that enable direct-to-consumer access and subscription models. Successful offerings typically combine a clear therapeutic rationale with delivery modes matched to the intended end-user environment and a distribution strategy that balances clinical endorsement with consumer access.

Regional strategic imperatives and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence regulatory, commercial, and manufacturing strategies

Regional dynamics vary substantially and shape strategic priorities for developers, payers, and providers. In the Americas, regulatory clarity and a growing ecosystem of value-based care pilots incentivize partnerships with payers and health systems, while commercial reimbursement pathways are maturing to support device and software integration into chronic care management. In Europe, Middle East & Africa, heterogeneity across national regulatory frameworks and reimbursement policies necessitates localized regulatory strategies and targeted health economic evidence to secure adoption, and collaborations with academic medical centers often support credibility and pilot program deployment. In Asia-Pacific, rapid digital health uptake, robust mobile penetration, and manufacturing clusters offer scale advantages, yet successful commercialization requires navigation of diverse regulatory regimes and localization of language and clinical pathways.

Across regions, differences in digital health literacy, clinician acceptance, and infrastructure maturity influence adoption speed. Cross-border partnerships, regional manufacturing, and localized evidence generation are common responses to these variations. Furthermore, regulatory convergence efforts and international standards for interoperability are creating opportunities for solutions that can be efficiently adapted across multiple jurisdictions. Companies that develop flexible regulatory plans and region-specific engagement strategies are best positioned to capture global opportunities while addressing local clinical and payer expectations.

How evolving competitive strategies, strategic alliances, and evidence-driven differentiation are reshaping product positioning and commercial models among digital therapeutic device companies

Competitive dynamics in the digital therapeutic devices space are characterized by the coexistence of established medical device manufacturers, digital health startups, and cross-sector entrants from consumer technology firms. Leading organizations are differentiating through clinical evidence generation, scalable platform architectures, and strategic alliances with pharmaceutical companies and health systems to embed products into standard care pathways. Venture-backed innovators often focus on rapid iteration and disease-specific indications, while incumbent manufacturers leverage regulatory know-how and supply chain scale to accelerate market entry for hybrid hardware-software offerings.

Strategic M&A and partnership activity is reshaping capability portfolios, with acquirers seeking assets that provide clinical validation, regulatory clearance, and established distribution relationships. Intellectual property strategies increasingly emphasize data models, algorithms, and integrated care pathways, and companies are investing in real-world evidence platforms to demonstrate longitudinal outcomes. As a result, business models are evolving from point-solution sales to subscription-based offerings, outcome-linked contracts, and bundled therapy packages that align incentives across stakeholders. Companies that can combine rigorous clinical proof, operational scalability, and payer-aligned value propositions will maintain differentiated positioning in an increasingly competitive landscape.

Actionable, prioritized recommendations for executives to align clinical evidence, interoperability, supply chain resilience, and commercial models for sustained growth

Industry leaders must pursue an integrated set of actions to secure clinical adoption and commercial success. First, prioritize generation of robust clinical evidence that aligns with payer and provider decision criteria, using pragmatic trial designs and real-world data to demonstrate meaningful outcomes over time. Second, design interoperable solutions that integrate with electronic health records and clinical workflows to reduce friction for clinicians and enable seamless data exchange. Third, develop flexible commercial models that include outcome-based contracting, pilot programs with health systems, and tiered pricing to reflect deployment contexts.

In addition, strengthen supply chain resilience through diversified sourcing, regional manufacturing partnerships, and component standardization to mitigate tariff and logistics risks. Invest in privacy-preserving data architectures and transparent consent mechanisms to build trust with patients and providers. Cultivate clinician champions and embed training resources to accelerate uptake, and deploy patient engagement strategies that combine behavioral science with usability testing to sustain adherence. Finally, engage early with regulatory bodies and payers to align evidence generation plans with reimbursement requirements, and consider strategic collaborations with pharmaceutical companies to leverage existing distribution channels and clinical trial infrastructure.

A rigorous mixed-methods research approach combining expert interviews, clinical evidence synthesis, regulatory analysis, and scenario testing to validate strategic implications

The research underpinning this analysis employed a mixed-methods approach combining primary qualitative interviews, secondary evidence synthesis, and targeted supply chain and regulatory analysis. Interviews were conducted with a cross-section of stakeholders including clinicians, payers, procurement leaders, device developers, and technology partners to capture practical insights into adoption barriers and enablers. Secondary analysis reviewed peer-reviewed clinical studies, regulatory guidance documents, technical standards for interoperability, and publicly available clinical trial registries to synthesize evidence on efficacy, safety, and implementation considerations.

Scenario analyses were used to explore the implications of supply chain disruptions and policy changes, while comparator mapping assessed differences in delivery modes and end-user contexts. The methodology emphasized triangulation of sources to validate themes and identify convergent findings. Quality assurance protocols included source verification and expert review to ensure that strategic implications are grounded in reliable clinical and operational evidence. Where evidence gaps were identified, they were explicitly noted as priorities for further empirical research and pilot deployments.

A decisive conclusion synthesizing clinical, regulatory, and operational priorities that determine leadership and sustained adoption in digital therapeutic devices

In conclusion, the digital therapeutic device landscape is maturing into a clinically driven and commercially viable segment of healthcare delivery, but success requires a disciplined alignment of evidence, regulation, and commercial strategy. Developers who invest in rigorous clinical validation, design for interoperability, and build payer-aligned commercial models will outpace competitors. At the same time, supply chain resilience and localization strategies are essential to mitigate trade-related cost pressures and ensure continuity of production and distribution.

Collaboration across stakeholders-including clinicians, payers, technology partners, and regulators-will accelerate integration of digital therapeutics into standard care pathways. Organizations that proactively address privacy, clinician adoption, and long-term real-world outcomes will not only meet regulatory and payer expectations but also deliver measurable patient benefit. Ultimately, a focus on demonstrable clinical value, scalable operational models, and adaptive regulatory strategies will determine which players lead the next phase of adoption and contribute to sustainable improvements in chronic disease management and population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Therapeutic Devices Market, by Therapeutic Area

  • 8.1. Cardiovascular
    • 8.1.1. Heart Failure
    • 8.1.2. Hypertension
  • 8.2. Diabetes Management
    • 8.2.1. Type 1 Diabetes
    • 8.2.2. Type 2 Diabetes
  • 8.3. Mental Health
    • 8.3.1. Anxiety
    • 8.3.2. Depression
    • 8.3.3. Stress Management
  • 8.4. Musculoskeletal
    • 8.4.1. Chronic Pain
    • 8.4.2. Physical Rehabilitation
  • 8.5. Respiratory
    • 8.5.1. Asthma
    • 8.5.2. Copd

9. Digital Therapeutic Devices Market, by Delivery Mode

  • 9.1. Mobile
  • 9.2. Vr Ar
  • 9.3. Wearable
  • 9.4. Web

10. Digital Therapeutic Devices Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online Platforms

11. Digital Therapeutic Devices Market, by End User

  • 11.1. Home Settings
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. Digital Therapeutic Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Digital Therapeutic Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Digital Therapeutic Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Digital Therapeutic Devices Market

16. China Digital Therapeutic Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 2Morrow, Inc.
  • 17.6. Akili Interactive Labs, Inc.
  • 17.7. Big Health Ltd.
  • 17.8. Biofourmis, Inc.
  • 17.9. Canary Health, Inc.
  • 17.10. Click Therapeutics, Inc.
  • 17.11. CureApp, Inc.
  • 17.12. DarioHealth Corp.
  • 17.13. Kaia Health Software GmbH
  • 17.14. MindMaze SA
  • 17.15. Noom, Inc.
  • 17.16. Omada Health, Inc.
  • 17.17. Pear Therapeutics, Inc.
  • 17.18. Propeller Health, Inc.
  • 17.19. Teladoc Health, Inc.
  • 17.20. Vida Health, Inc.
  • 17.21. WellDoc, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ANXIETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ANXIETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ANXIETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY STRESS MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY STRESS MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY STRESS MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY PHYSICAL REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY PHYSICAL REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY PHYSICAL REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MOBILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MOBILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MOBILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY VR AR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY VR AR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY VR AR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEARABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEARABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEARABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOME SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOME SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOME SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 223. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)